BRIEF published on 11/04/2024 at 11:51, 5 months 26 days ago Acticor Biotech : Publication des résultats financiers semestriels 2024 Résultats Semestriels Biotechnologie Finance Redressement Judiciaire Glenzocimab
BRIEF published on 11/04/2024 at 11:51, 5 months 26 days ago Acticor Biotech: Publication of 2024 half-year financial results Biotechnology Finance Half-year Results Glenzocimab Judicial Recovery
PRESS RELEASE published on 11/04/2024 at 11:46, 5 months 26 days ago Informations privilégiées / Communiqué sur comptes, résultats Acticor Biotech publie ses résultats financiers semestriels 2024 et annonce le repositionnement du glenzocimab dans le traitement de l’infarctus du myocarde avec élévation du segment ST (STEMI) Résultats Financiers ACTICOR BIOTECH Glenzocimab Repositionnement Infarctus Du Myocarde
PRESS RELEASE published on 11/04/2024 at 11:46, 5 months 26 days ago Inside Information / News release on accounts, results Acticor Biotech publishes its half-year financial results for 2024, highlighting repositioning of glenzocimab in STEMI treatment, receivership proceedings extension, and shareholder approvals Repositioning Shareholder Approvals ACTICOR BIOTECH Glenzocimab Half-year Financial Results
BRIEF published on 10/11/2024 at 17:50, 6 months 18 days ago Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment Clinical Trials Myocardial Infarction ACTICOR BIOTECH Glenzocimab Cardiovascular Treatment
BRIEF published on 10/11/2024 at 17:50, 6 months 18 days ago Acticor Biotech fait progresser le Glenzocimab dans le traitement de l'infarctus du myocarde Essais Cliniques ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde Traitement Cardiovasculaire
PRESS RELEASE published on 10/11/2024 at 17:45, 6 months 18 days ago Inside Information / Other news releases Acticor Biotech repositions glenzocimab in the treatment of myocardial infarction, evaluating efficacy and safety in phase 2 studies LIBERATE and GLORIA. Clinical trials aim to reduce infarct size and prevent complications Clinical Trials Phase 2b Myocardial Infarction ACTICOR BIOTECH Glenzocimab
PRESS RELEASE published on 10/11/2024 at 17:45, 6 months 18 days ago Informations privilégiées / Autres communiqués Repositionnement de glenzocimab dans le traitement de l'infarctus du myocarde par Acticor Biotech. Nouvelle étude de phase 2b LIBERATE et préparation de l'étude GLORIA Traitement Étude Clinique ACTICOR BIOTECH Glenzocimab Infarctus Du Myocarde
BRIEF published on 07/09/2024 at 20:50, 9 months 20 days ago Acticor Biotech Reports 2023 Financial Results Financial Report Annual Results Capital Raising ACTICOR BIOTECH Glenzocimab
BRIEF published on 07/09/2024 at 20:50, 9 months 20 days ago Acticor Biotech publie ses résultats financiers pour 2023 Résultats Annuels Rapport Financier ACTICOR BIOTECH Glenzocimab Levée De Capitaux
Published on 04/30/2025 at 13:30, 18 minutes ago Galloper Announces Closing of Non-Brokered Private Placement
Published on 04/30/2025 at 13:30, 18 minutes ago Northern Superior Highlights ONGold's Appointment of Vice-President Exploration and Monument Bay Project Update
Published on 04/30/2025 at 12:00, 1 hour 48 minutes ago Banyan Provides Update for 2025 Diamond Drill Exploration Program at the AurMac Project, Yukon, Canada
Published on 04/30/2025 at 08:00, 5 hours 48 minutes ago Argo Blockchain PLC Announces Financial Update and Listing Suspension Request
Published on 04/30/2025 at 13:35, 12 minutes ago ARYZTA announces details of the implementation of the planned reverse share split
Published on 04/30/2025 at 13:30, 18 minutes ago Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Published on 04/30/2025 at 13:16, 31 minutes ago Knorr-Bremse’s Annual General Meeting approves 7% dividend increase and elects Stephan Sturm to the Supervisory Board
Published on 04/30/2025 at 08:30, 5 hours 18 minutes ago Mise à disposition des documents préparatoires à l’Assemblée Générale mixte
Published on 04/29/2025 at 19:02, 18 hours 45 minutes ago LNA SANTE : Mise à disposition du document d'enregistrement universel 2024
Published on 04/29/2025 at 18:22, 19 hours 26 minutes ago BIO-INOX : RESULTATS ANNUELS 2024 : CHIFFRE D'AFFAIRES +16,4% - RESULTAT NET +75,1%
Published on 04/29/2025 at 18:12, 19 hours 36 minutes ago 250429 BENETEAU Avis de mise à disposition de documents
